Thymoquinone alleviates cisplatin-induced kidney damage by reducing apoptosis in a rat model
Heliyon, ISSN: 2405-8440, Vol: 10, Issue: 2, Page: e24840
2024
- 2Citations
- 15Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Most Recent News
Qinghai University Affiliated Hospital Researchers Have Provided New Study Findings on Apoptosis (Thymoquinone alleviates cisplatin-induced kidney damage by reducing apoptosis in a rat model)
2024 FEB 02 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Daily -- Fresh data on apoptosis are presented in a
Article Description
The aim of the study was to compare the ameliorating effects of thymoquinone at various dosages on cisplatin-induced renal toxicity, and to investigate its effects on cisplatin-induced nephrocyte apoptosis via the mitochondrial pathway in a rat model. A rat model of cisplatin-induced renal damage was established, with thymoquinone treatment groups (receiving 1, 3, 5, 10, or 20 mg/kg of thymoquinone). We determined serum creatinine (Cr) and blood urea nitrogen (BUN), measured the expression of the anti-apoptotic protein Bcl-2, the pro-apoptotic protein Bax, caspase-3, kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) in renal tissue. Additionally, we observed pathological changes in renal tissue and performed paller score for renal tubule injury. Relative to the control, the cisplatin group exhibited significantly elevated Bax, caspase-3, NGAL and KIM-1 expression, elevated serum Cr and BUN concentrations and significantly reduced Bcl-2 expression ( P < 0.05). Histopathological examination of cisplatin-treated group revealed vacuolar degeneration, tubular epithelial cell swelling, and an absence of brush margins on renal tubules. Paller score was significantly elevated in the cisplatin group relative to the normal control group. Thymoquinone dose-dependently ameliorated these effects. Thymoquinone at 1–20 mg/kg improved cisplatin-induced renal dysfunction in rats. This protective effect is related to the inhibition of mitochondria-mediated apoptosis.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2405844024008715; http://dx.doi.org/10.1016/j.heliyon.2024.e24840; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85182905881&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/38304804; https://linkinghub.elsevier.com/retrieve/pii/S2405844024008715; https://dx.doi.org/10.1016/j.heliyon.2024.e24840
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know